Vaishali A. Kilor
Research Subjects
Vaishali A. Kilor has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Nidhi Sapkal
Gurunanak College of Pharmacy, Kashi Nagar, Near Dixit Nagar, Nari Road, Nagpur, MS, India
2 shared publicationsAnwar Daud
Zim laboratories Ltd., Kalmeshwar, Nagpur-44002
1 shared publicationBharti D. Shewale
H. R. Patel Women’s College of Pharmacy
1 shared publicationJasmine G. Awari
RTM Nagpur University Nagpur
1 shared publication- Kumar Pratyush
Department of Pharmaceutical Chemistry, SVKM NMIMS Global University School of Pharmacy and Technology Management, Dhule, India
1 shared publication - Kunal Badrinarayan Banode
Taywade College of Pharmacy, Koradi, India
1 shared publication
Latest Publications
- 6 March 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (3) , 262
Development and Optimization of 3D-Printed Orally Dissolving Films of Vitamin D₃ Using a Quality by Design Approach
- 6 March 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (3) , 262
Development and Optimization of 3D-Printed Orally Dissolving Films of Vitamin D₃ Using a Quality by Design Approach
- 27 March 2025
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 18 (3) , 1456-1465
Review of clinical studies of herbal products as a treatment option in recurrent Aphthous stomatitis
Recurrent aphthous stomatitis (RAS) is the repeated occurrence of lesions in the intraoral sites having diverse etiology leading to pain, inflammation, and difficulty in eating and speaking. Common treatment options available for RAS are analgesics, corticosteroids, local anesthetics, and antimicrobial agents. The purpose is to reduce the intensity of pain, inflammation, and duration of the ulcer. All the above-mentioned medications if used for a longer duration may result in several complications including antibiotic resistance. It is commonly observed that patients suffering from RAS initiate self-treatment like the application of honey, and turmeric to ulcers, chewing of guava leaves, beetle leaves, etc., based on traditional knowledge which results in inconsistent relief and ultimately treatment shifts towards the use of corticosteroids, analgesic as well as antibiotics. There is a need for evidence-based systematic studies that lead to the availability of formulations containing herbal medicines for guaranteed quick relief from pain and reducing recurrence of mouth ulcers. Thus, to prove efficacy of traditional herbal medicine, several clinical trials are being done where these medicines are used as single extract for topical application. The present study aims to critically assess the available data of clinical trials on the topical treatment of RAS using plant-based medicines and identify the most promising plant-based medicine that gives quick relief from RAS.
- 27 March 2025
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 18 (3) , 1456-1465
Review of clinical studies of herbal products as a treatment option in recurrent Aphthous stomatitis
Recurrent aphthous stomatitis (RAS) is the repeated occurrence of lesions in the intraoral sites having diverse etiology leading to pain, inflammation, and difficulty in eating and speaking. Common treatment options available for RAS are analgesics, corticosteroids, local anesthetics, and antimicrobial agents. The purpose is to reduce the intensity of pain, inflammation, and duration of the ulcer. All the above-mentioned medications if used for a longer duration may result in several complications including antibiotic resistance. It is commonly observed that patients suffering from RAS initiate self-treatment like the application of honey, and turmeric to ulcers, chewing of guava leaves, beetle leaves, etc., based on traditional knowledge which results in inconsistent relief and ultimately treatment shifts towards the use of corticosteroids, analgesic as well as antibiotics. There is a need for evidence-based systematic studies that lead to the availability of formulations containing herbal medicines for guaranteed quick relief from pain and reducing recurrence of mouth ulcers. Thus, to prove efficacy of traditional herbal medicine, several clinical trials are being done where these medicines are used as single extract for topical application. The present study aims to critically assess the available data of clinical trials on the topical treatment of RAS using plant-based medicines and identify the most promising plant-based medicine that gives quick relief from RAS.
- Open Access
- 10 March 2017
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- Vol. 9 (2) , 28-33
DEVELOPMENT OF STABLE NANOSUSPENSION LOADED ORAL FILMS OF GLIMEPIRIDE WITH IMPROVED BIOAVAILABILITY
Objective: In the present work attempt has been made to stabilize optimized nanosuspensions of glimepiride by solidification using a novel Oral Thin Film (OTF) formulation.Methods: Nanosuspensions were characterized for particle size, zeta potential as well as in vitro dissolution profile. As nanosuspensions are prone to destabilization by Ostwald’s ripening or agglomeration/aggregation, OTF formulation as a novel approach for stabilization through solidification of optimized nanosuspension was attempted. OTF formulation method is a simple, easy and scalable method for the preparation of solid oral dosage form. Prepared formulations were evaluated for physicochemical parameters like folding endurance, disintegration time, tensile strength, in vitro drug release, in vivo bioavailability and stability.Results: The mean particle size of the nanoparticles in OTF was found to be 57.2 nm. It was observed from the results of in vivo bioavailability studies that high plasma drug concentrations(Cmax) were achieved for nanosuspension loaded OTF (NSOTF) i.e. 4900 ng/ml as compared to marketed oral formulation (Cmax-2900 ng/ml). Results of the stability studies indicated that nanosize of the particles was retained even after 3 mo of the study.Conclusion: Therefore it can be concluded that OTF formulation has a potential for stabilization of nanosuspensions.
- 10 March 2017
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- Vol. 9 (2) , 28-33
Open AccessDEVELOPMENT OF STABLE NANOSUSPENSION LOADED ORAL FILMS OF GLIMEPIRIDE WITH IMPROVED BIOAVAILABILITY
Objective: In the present work attempt has been made to stabilize optimized nanosuspensions of glimepiride by solidification using a novel Oral Thin Film (OTF) formulation.Methods: Nanosuspensions were characterized for particle size, zeta potential as well as in vitro dissolution profile. As nanosuspensions are prone to destabilization by Ostwald’s ripening or agglomeration/aggregation, OTF formulation as a novel approach for stabilization through solidification of optimized nanosuspension was attempted. OTF formulation method is a simple, easy and scalable method for the preparation of solid oral dosage form. Prepared formulations were evaluated for physicochemical parameters like folding endurance, disintegration time, tensile strength, in vitro drug release, in vivo bioavailability and stability.Results: The mean particle size of the nanoparticles in OTF was found to be 57.2 nm. It was observed from the results of in vivo bioavailability studies that high plasma drug concentrations(Cmax) were achieved for nanosuspension loaded OTF (NSOTF) i.e. 4900 ng/ml as compared to marketed oral formulation (Cmax-2900 ng/ml). Results of the stability studies indicated that nanosize of the particles was retained even after 3 mo of the study.Conclusion: Therefore it can be concluded that OTF formulation has a potential for stabilization of nanosuspensions.
- 3 March 2010
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 11 (1) , 336-343
Development and Characterization of Enteric-Coated Immediate-Release Pellets of Aceclofenac by Extrusion/Spheronization Technique Using κ-Carrageenan as a Pelletizing Agent
In the present study, an attempt was made to prepare immediate-release enteric-coated pellets of aceclofenac, a poorly soluble nonsteroidal anti-inflammatory drug that has a gastrointestinal intolerance as its serious side effect. Formulation of enteric-coated pellets with improved solubility of aceclofenac could address both of these problems. To achieve these goals, pellets were prepared by extrusion–spheronization method using pelletizing agents that can contribute to the faster disintegration and thereby improve the solubility of the drug. Different disintegrants like β-cyclodextrin, kollidon CL, Ac-Di-Sol, and sodium starch glycolate were tried in order to further improve disintegration time. The pellets were characterized for drug content, particle size distribution, flow properties, infrared spectroscopy, surface morphology, disintegration rate, and dissolution profile. The formulations, which showed best disintegration and dissolution profiles, were coated with Eudragit L100-55, an enteric-coated polymer which does not dissolve at gastric pH but dissolves at intestinal pH, releasing the drug immediately in the dissolution medium. The optimized enteric-coated formulation containing 20% κ-carrageenan, lactose, and sodium starch glycolate as a disintegrant did inhibit the release of the drug for 2 h in 0.1 N HCl, whereas 87% of the drug was released within 45 min. The improvement was substantial when it was compared with solubility of pure drug under the same conditions. Thus, dissolution profiles suggested that combination of κ-carrageenan and sodium starch glycolate resulted into fast-disintegrating, immediate-release pellets, overcoming the bioavailability problem of the poorly soluble drug, aceclofenac, and enteric coating of these pellets avoids the exposure of aceclofenac to ulcer-prone areas of the gastrointestinal tract.
- 3 March 2010
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 11 (1) , 336-343
Development and Characterization of Enteric-Coated Immediate-Release Pellets of Aceclofenac by Extrusion/Spheronization Technique Using κ-Carrageenan as a Pelletizing Agent
In the present study, an attempt was made to prepare immediate-release enteric-coated pellets of aceclofenac, a poorly soluble nonsteroidal anti-inflammatory drug that has a gastrointestinal intolerance as its serious side effect. Formulation of enteric-coated pellets with improved solubility of aceclofenac could address both of these problems. To achieve these goals, pellets were prepared by extrusion–spheronization method using pelletizing agents that can contribute to the faster disintegration and thereby improve the solubility of the drug. Different disintegrants like β-cyclodextrin, kollidon CL, Ac-Di-Sol, and sodium starch glycolate were tried in order to further improve disintegration time. The pellets were characterized for drug content, particle size distribution, flow properties, infrared spectroscopy, surface morphology, disintegration rate, and dissolution profile. The formulations, which showed best disintegration and dissolution profiles, were coated with Eudragit L100-55, an enteric-coated polymer which does not dissolve at gastric pH but dissolves at intestinal pH, releasing the drug immediately in the dissolution medium. The optimized enteric-coated formulation containing 20% κ-carrageenan, lactose, and sodium starch glycolate as a disintegrant did inhibit the release of the drug for 2 h in 0.1 N HCl, whereas 87% of the drug was released within 45 min. The improvement was substantial when it was compared with solubility of pure drug under the same conditions. Thus, dissolution profiles suggested that combination of κ-carrageenan and sodium starch glycolate resulted into fast-disintegrating, immediate-release pellets, overcoming the bioavailability problem of the poorly soluble drug, aceclofenac, and enteric coating of these pellets avoids the exposure of aceclofenac to ulcer-prone areas of the gastrointestinal tract.